Houman Mesghali has a diverse professional background in the pharmaceutical industry, with experience at Teva Pharmaceuticals and MD Anderson Cancer Center. Currently, Mesghali is the Co-Founder and COO at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. Mesghali holds an MBA in Finance & Management from The Johns Hopkins University - Carey Business School and an M.Sc. in Molecular Biology from the University of Maryland.
This person is not in any offices
CTMC / A joint venture between Resilience + MD Anderson Cancer Center
Cell Therapy Manufacturing Center (CTMC) is a joint venture between Resilience and MD Anderson Cancer Center. CTMC was created to bring together the leading complex biologics manufacturing technology organization and the #1 clinical cancer center to enable innovation from academia and biotech to accelerate Cell Therapy’s impact for cancer patients.
Employees
51-200